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Hypoxia-inducible factor-1 (HIF-1)a expression was studied in the gastric carcinogenesis sequence and as a prognostic factor in
surgically resected gastric and gastro-oesophageal junction tumours. Protein expression was examined using immunohistochemistry
on formalin-fixed biopsies of normal mucosa (n¼20), Helicobacter pylori associated gastritis (n¼24), intestinal metaplasia (n¼24),
dysplasia (n¼12) and intestinal (n¼19) and diffuse (n¼21) adenocarcinoma. The relationship between HIF-1a expression and
prognosis was assessed in resection specimens from 177 patients with gastric and gastro-oesophageal junction adenocarcinoma.
Hypoxia-inducible factor-1a expression was not observed in normal gastric mucosa but increased in density (Po0.01) and intensity
(Po0.01) with progression from H. pylori-associated gastritis, intestinal metaplasia, dysplasia to adenocarcinoma. The pattern of
staining in the resection specimens was focally positive in 49 (28%) and at the invasive tumour edge in 41 (23%). Invasive edge
expression was associated with lymph node metastases (P¼0.034), advanced TNM stage (P¼0.001) and was an adverse prognostic
factor for cancer-specific survival (P¼0.019). In univariate analysis and in comparison with tumours not expressing HIF-1a, invasive
edge staining was associated with a hazard ratio of 1.6 (95% CI 1.0 2.5) and focally positive staining a hazard ratio of 0.7 (95% CI
0.5 1.2). Hypoxia-inducible factor-1a lost prognostic significance in multivariate analysis. The results suggest HIF-1a is involved in
gastric carcinogenesis and disease progression, but is only a weak prognostic factor for survival.
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Tumour hypoxia is now recognised as a key factor driving the
development of malignancy, and the master regulatory protein in
the response of cells to changing oxygen levels is hypoxia-
inducible factor-1 (HIF-1). Hypoxia-inducible factor-1 consists of
a and b-subunits which are both members of the helix-loop-helix
family of transcription factors (Semenza, 2003). The b-subunit is
constitutively expressed and its activity is controlled in an oxygen-
independent manner. The a-subunit is ubiquitinated and degraded
in normoxia, but stabilised in hypoxia. In the hypoxic environ-
ment, HIF-1a dimerises with HIF-1b and binds to hypoxia-
responsive elements (HRE) within the nucleus. A wide variety of
genes, including VEGF, Glut-1, CA9, erythropoietin and iNOS are
known to have HREs and are activated by HIF-1a. Non-hypoxic
activators are now known to include growth factors, cytokines,
tumour suppressor genes, oncogenes, viruses and bacteria
(Griffiths et al, 2005).
Hypoxia-inducible factor-1a activity appears to be a very early
event in carcinogenesis and the protein is expressed before
histological evidence of angiogenesis or invasion (Zhong et al,
1999). Zhong et al (1999) first observed HIF-1a expression in a few
cases of pre-malignant breast, prostatic and colonic tissue.
Subsequent studies with greater numbers of patients showed that
HIF-1a expression is involved, and progressively increased
expression has been observed in the pre-malignant phases and
developmental steps of breast (Bos et al, 2001), skin (Costa et al,
2001) and cervical (Acs et al, 2003) cancer. In prostatic carcinoma,
HIF-1a expression was highly expressed in the precursor lesion,
prostatic intra-epithelial neoplasia (Zhong et al, 2004).
Histologically, gastric cancers are classified into two types:
diffuse and intestinal (Lauren, 1965). For the development of
intestinal gastric cancer, a multistep process involving a progres-
sive cascade of molecular and morphological changes has been
proposed by Correa (2004). Diffuse tumours have no known
pre-malignant precursor lesions. For both types of tumour the
carcinogenesis process is believed to be initiated by Helicobacter
pylori infection and the risk of gastric cancer development has
been related to H. pylori strain type, other environmental factors,
host genetic factors and immune-related polymorphisms (Peek
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sand Blaser, 2002; Nardone et al, 2004). Although H. pylori can
directly or indirectly alter intracellular signalling in the gastric
mucosa, leading to increased proliferation and apoptosis, host
inflammation appears to be of key importance in tumour
development. Additional mutational genetic and epigenetic events
in the tumour or neighbouring cells lead to progressive tumour
development. These events and the inflammatory process are
believed to adaptively transform H. pylori-induced chronic
gastritis into intestinal metaplasia, epithelial dysplasia and finally
intestinal-type carcinoma. Hypoxia-inducible factor-1a has been
implicated in this process: a cell line study has shown that reactive
oxygen species (ROS), produced by H. pylori, stabilise HIF-1a,
leading to increased expression (Park et al, 2003).
Hypoxia-inducible factor-1a is expressed in a variety of human
cancers (Zhong et al, 1999), and has been linked with a poor
prognosis in patients who received radiotherapy (Aebersold et al,
2001), chemotherapy (Sohda et al, 2004) or surgery (Kurokawa
et al, 2003). As such, there is currently interest in the use of HIF-1a
inhibition as a cancer therapeutic strategy. Two studies revealed
encouraging results in murine models of gastric cancer (Yeo et al,
2003; Stoeltzing et al, 2004). They used either pharmacological or
genetic inhibition of HIF-1a, which resulted in dramatic effects on
tumour vascularisation and reduced growth of xenografts derived
from human gastric cancer cells. However, studies of HIF-1a
expression have been conflicting in several tumour subsites,
including cervical, lung and ovarian cancer. Some studies have
related high HIF-1a expression with an improved prognosis (Volm
and Koomagi, 2000; Beasley et al, 2002). Although HIF-1a
expression was associated with a poor prognosis in gastrointestinal
stromal tumours of the stomach (Takahashi et al, 2003; Chen et al,
2005b), there are conflicting prognostic data in patients with
gastric adenocarcinoma (Mizokami et al, 2006; Sumiyoshi et al,
2006; Urano et al, 2006). These studies involved Japanese patients,
where there is a predilection for distal gastric cancer and relative
lack of gastro-oesophageal junction tumours. Therefore, the
prognostic effect of HIF-1a expression in tumour locations
more representative of the UK population remains unknown. Also
HIF-1a expression has yet to be studied in a gastric carcinogenesis
model.
Therefore, the aims of this study were to investigate HIF-1a
expression by immunohistochemistry in the pre-malignant and
malignant gastric tissue progression sequence, and to assess the
prognostic value of HIF-1a expression in surgically treated gastric
and gastro-oesophageal cancer patients.
MATERIALS AND METHODS
Human tissue specimens
Tissue specimens were obtained from the histopathology archive
of the Department of Histopathology, South Manchester University
Hospitals NHS Trust. The study was approved by the South
Manchester Ethics Committee.
Gastric biopsies specimens
Formalin-fixed endoscopic gastric biopsy samples of normal
gastric mucosa (n¼20), H. pylori associated gastritis (n¼20),
intestinal metaplasia (n¼20), epithelial dysplasia (n¼12) and
intestinal (n¼19) and diffuse (n¼21) type gastric adenocarcinoma
were obtained. Endoscopy reports were obtained to ensure the
correct biopsy location. Four of the biopsies had both H. pylori
infected mucosa and intestinal metaplasia tissue. The haemato-
xylin and eosin slides were reassessed by a consultant pathologist
(SP) to ensure correct classification. All cases of H. pylori-
associated gastritis showed significant numbers of organisms. The
epithelial dysplasia group were classified as low (n¼6) or high
(n¼6) grade. Intestinal metaplasia was present in six out of the 12
dysplasia biopsies.
Surgically treated patients
A retrospectively compiled database was established of 251
consecutive patients with primary gastric and gastro-oesophageal
junction tumours who underwent surgery at the South Manchester
University Hospitals NHS Trust between 1995 and 2004. The
Siewert classification was used to classify gastro-oesophageal
junction tumours (Siewert and Stein, 1998). Patients who had
either Siewert Type I gastro-oesophageal tumours (n¼22), neo-
adjuvant therapy (n¼31), emergency surgery (n¼1), completion
gastrectomy (n¼6) or died after surgery (n¼25) were excluded
from the study. The study group therefore comprised 177 patients
(125 males) with a median age of 68 (range 49–85) years. There
were 76 Siewert type II, 21 type III gastro-oesophageal junction
tumours and 80 non-cardia gastric cancers. Patients underwent
either partial or subtotal gastrectomies (n¼45), total gastrectomy
(n¼44), proximal gastrectomy (n¼4) or oesophago-gastrectomy
(n¼84). Selected patients underwent additional surgical resection
of the spleen (n¼21) and spleen with distal pancreas (n¼5). One
hundred and thirteen patients (64%) underwent a potentially
curative resection (R0 resection), defined as complete macroscopic
and microscopic removal of the tumour on intraoperative
assessment and subsequent histopathological evaluation. Fifty-
four patients (31%) had residual microscopic disease (R1
resection), whereas 10 patients (6%) had residual macroscopic
disease (R2 resection). After surgery, patients were followed in
the surgical outpatient clinic. Hospital notes of the patients were
reviewed and, if necessary, the local cancer registry or patient’s
general practitioner were contacted to complete case follow-up.
Immunohistochemical staining of HIF-1a
The best tissue section for immunohistochemistry was selected and
the corresponding formalin-fixed, paraffin-embedded resection
specimen obtained. As deterioration in immunohistochemical
staining occurs in stored sections (Bertheau et al, 1998; Olapade-
Olaopa et al, 2001), specimens were stained within 2 months of
cutting. Immunohistochemical detection of HIF-1a was performed
using the Tyramide Signal Amplification System (NEN Life
Sciences, Boston), which is based on a streptavidin–biotin–
horseradish peroxidase complex formation. Sections 4mm thick
were deparaffinised and the antigen retrieved by microwaving in
10mM citrate buffer (pH 6.0) for 25min followed by blocking steps
according to the manufacturer’s protocol. Mouse monoclonal
antibody (610958, BD Biosciences, diluted 1:100) was applied and
the slides incubated overnight at 41C. The secondary antibody,
biotinylated rabbit anti-mouse (DakoCytomation, Denmark), was
applied with additional blocking precautions employed to mini-
mise the amplification of nonspecific background (Kim et al,
2003). The antibody was visualised using diaminobenzidine
(DakoCytomation, Denmark) and the sections counterstained with
haematoxylin, dehydrated and mounted. Substitution of the
primary antibody with the identical concentration of mouse
immunoglobulins IgG1 (DakoCytomation, Denmark) served as
negative controls. Batch-to-batch variation was assessed by
choosing two sections showing high and low HIF-1a expression
and running additional sections from these biopsies with each
batch.
Assessment of HIF-1a staining in the tissue sections
Only tumour nuclear HIF-1a staining was scored using a method
modified from the literature that was previously used on gastric
tissue (Ito et al, 2003). The scoring system was as follows: 0, no
nuclear staining; 1, o2% nuclear staining; 2, 2–10% nuclear
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sstaining; 3, 10–29% nuclear staining; and 4, 430% nuclear
staining. Nuclear staining intensity in the gastric biopsies was
scored as weak, moderate or strong. Scoring was performed in a
double-blind manner by two independent investigators (SP, EAG).
Any disagreement was resolved by discussion to obtain a final
score.
Statistics
The non-parametric Jonckheere–Terpstra test was used to identify
ordered differences among the biopsy categories in the gastric
carcinogenesis sequence. With this test, the null hypothesis is that
the distribution does not differ across ordered categories. The
w
2-test was used to correlate HIF-1a expression and the various
clinical and pathological characteristics of the patients studied.
Survival time was measured as the time from the date of surgery
until death or last follow-up appointment. Overall survival and
cancer-specific survival were used as end points. Univariate
survival analyses were performed using the Kaplan–Meier
method. Factors were compared using the Cox proportional
hazards model and log-rank tests. Multivariate survival analysis
was performed on factors which achieved statistical significance
(Po0.05) in univariate analysis, using the Cox proportional
hazards model to identify independent predictors of survival.
RESULTS
Expression of HIF-1a in gastric biopsy specimens
Photomicrographs of HIF-1a staining in the different tissues are
shown in Figure 1. Hypoxia-inducible factor-1a was not seen in
biopsies of normal gastric mucosa, but expression increased in
density and intensity with progression to gastric cancer
(P¼0.0001, Table 1). In the H. pylori associated gastritis biopsies,
HIF-1a was expressed focally, with only a small percentage of
weakly positive mucosal cells identified. The positive cells tended
to be in small clusters or were part of the same crypt. Staining was
predominantly in areas of inflammation associated with H. pylori.
Ten of the 24 intestinal metaplastic biopsies expressed HIF-1a, and
the intensity of staining was increased compared with the H. pylori
associated gastritis, with one-third showing moderate nuclear
staining. In the biopsies of intestinal metaplasia, HIF-1a was
expressed predominantly in the metaplastic tissue areas. The
nuclei of cells forming crypts containing goblet cells stained
positively, whereas adjacent non-metaplastic crypts were negative.
Hypoxia-inducible factor-1a was seen in half of the gastric
dysplasia samples. Staining appeared to be more prevalent in high
(four of six positive) vs low (two of six positive) grade lesions. The
majority of intestinal-type adenocarcinoma specimens showed
nuclear staining expression, with half staining strongly for HIF-1a.
The highest percentages of expression were found in the diffuse-
type adenocarcinoma biopsies.
Expression of HIF-1a in surgically resected specimens
The predominant staining pattern observed in adenocarcinomas
was focal in nature, with small numbers of positive cells adjacent
to each other, rather than scattered single positive cells
(Figure 1G). Individual malignant glands showed positive staining
in either the majority or none of the cells. There was increased
staining within superficial malignant cells in direct contact with
the gastric lumen that did not appear artefactual. In the majority of
cases, there was diffuse inflammation and necrosis of variable
degree throughout the tumour with an associated desmoplastic
reaction, as is often the case in gastric adenocarcinoma. It was,
therefore, not possible to assess reliably staining patterns
associated with inflammation and necrosis compared with non-
inflammatory areas. However, it was noted that tumour cells
adjacent to areas of surface ulceration that were peri-necrotic in
nature showed increased levels of HIF-1a expression. Some of the
tumours studied had large solid areas of malignant cells that
showed no increase in HIF-1a expression within the central region
of the cell groups but a tendency for increased expression in the
peripheral layers of cells. Malignant cells at the invasive edge of
the tumour tended to show increased staining that was more
pronounced if the invasive edge was penetrating the subserosal
tissue (Figure 1H). In some cases, the only positive tumour cells
were those that had invaded through the muscularis propria into
subserosal fat. It was interesting to note that macrophages and
endothelial cells associated with tumour cells within the subserosal
tissue also showed strong staining for HIF-1a. This feature was not
seen in other layers of the gastric wall. In some cases, the adjacent
non-neoplastic mucosa showed intestinal metaplasia that was
associated with increased expression of HIF-1a, as seen in the
biopsy specimens.
AB
CD
EF
GH
Figure 1 Photomicrographs of HIF-1a immunohistochemistry in the
gastric cancer progression sequence showing no staining in normal mucosa
(A), weak nuclear staining in mucosal cells in H. pylori gastritis (B),
moderate staining in intestinal metaplastia (C), distinct nuclear staining in
high grade dysplasia (D), and strong staining in well (E) and poorly (F)
differentiated intestinal adenocarcinoma (E) and revealing moderate
HIF-1a staining; (D) High grade dysplasia showing distinct nuclear HIF-1a
staining. Well (E) and poorly (F) differentiated intestinal adenocarcinoma
showing distinct strong nuclear HIF-1a staining. Photomicrographs of
HIF-1a immunohistochemistry in resected gastric cancer specimens
showing focally positive (G) and invasive edge (H) patterns of staining.
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sIn addition to the predominantly nuclear expression, cytoplas-
mic staining was also observed, but was not scored. In 83 tumour
sections (47%), no HIF-1a nuclear immunostaining was observed.
Positive nuclear staining was as follows: o2% staining in 62
sections (35%), 2–10% staining in 21 sections (12%), 11–30%
staining seven sections (4%) and 430% staining in three sections
(2%). Staining pattern was focally positive in 49 (28%), at the
invasive tumour edge in 41 (23%) and diffusely positive in three
(2%). Staining intensity was similar between slides and not scored
in the surgically resected specimens. One slide was lost after
staining. All negative controls showed no immunoreactivity.
Scoring was repeatable with good inter-observer agreement
(r¼0.90, P¼0.0001).
HIF-1a expression and clinicopathological features
For correlation with clinicopathological features, HIF-1a expres-
sion was categorised as negative (score 0) or positive (scores
1/2/3/4). Tables 2 and 3 summarise the distributions of patients
according to tumour HIF-1a expression (positive vs negative) and
staining pattern (negative, focal or invasive edge). Tumours that
expressed HIF-1a tended to have a higher overall TNM stage
compared with those that did not (P¼0.045). There were no
statistically significant differences between HIF-1a positive and
negative tumours regarding differentiation, Lauren type, T stage,
N stage or M stage (Table 2). When a higher cutoff was used to
determine HIF-1a positivity (42% staining), no statistically
significant relationships were seen between high HIF-1a expres-
sion and clinicopathological features. There were no statistically
significant differences between HIF-1a positive and negative
tumours regarding differentiation, Lauren type, T stage, N stage
or M stage (Table 2). Hypoxia-inducible factor-1a expression at the
invasive edge was associated with lymph node metastases
(P¼0.034) and advanced TNM stage (P¼0.001).
HIF-1a expression and patient survival
At the time of analysis, 51 patients were alive with a median follow-
up of 48 months (range 13–118) months, whilst 107 had died of
disease with a median time to death of 14 (range 2–74) months.
There were 16 inter-current deaths from other causes. Table 4
summarises the results of univariate analyses of overall and
cancer-specific survival. The results for HIF-1a expression in
relation to cancer-specific survival are illustrated in Figure 2.
There was no difference in overall and cancer-specific survival in
patients with HIF-1a negative vs positive tumours, either for the
group as a whole, when gastric and gastro-oesophageal junction
tumours were analysed separately or when a higher cutoff (42%
staining) was used to determine positivity. However, in univariate
analysis HIF-1a expression pattern was a significant prognostic
factor for overall (P¼0.016, log-rank test) and cancer-specific
(P¼0.019, log-rank test) survival. Using the Cox proportional
hazards model and in comparison with tumours not expressing
HIF-1a, invasive edge staining was associated with a hazard ratio
of 1.6 (95% CI 1.0–2.5) and focally positive staining a hazard ratio
of 0.7 (95% CI 0.5–1.2). Other significant factors in univariate
analyses were tumour differentiation, T stage, N stage, overall
TNM stage and R classification (Table 4). In multivariate analysis,
only overall TNM stage and R classification retained prognostic
significance for overall and cancer-specific survival. For example,
R1/2 compared with R0 resections had a hazard ratio for cancer-
specific survival of 2.0 (95% CI 1.2–3.2; P¼0.006) and TNM stage
4 vs 1 disease was associated with a hazard ratio of 4.5 (95% CI
1.8–11.1; P¼0.001).
Table 1 HIF-1a expression in the gastric cancer progression sequence
HIF-1a density HIF-1a intensity
Biopsy type n 0% o2% 2–10% 11–30% 430% Weak Mod Strong
Normal mucosa 20 20 — — — — — — —
H. pylori gastritis 24
a 12 12 — — — 11 1 —
Intestinal metaplasia 24
a 14 8 2 — — 7 3 —
Dysplasia 12 6 2 3 1 — 1 2 3
Intestinal type adeno 19 3 7 5 3 1 6 2 8
Diffuse type adeno 21 11 3 2 2 3 1 0 9
Abbreviation: HIF¼hypoxia inducible factor.
aFour biopsies had areas of H. pylori gastritis and intestinal metasplasia and were included in both subcategories. The increases in
HIF-1a density (P¼0.0001) and intensity (P¼0.0001) were highly statistically significant (Jonckheere–Terpstra test).
Table 2 Distribution of 176
a patients according to tumour HIF-1a
expression
HIF-1a expression
Factor Negative Positive P*
Differentiation
Well 12 6
Mod 33 34
Poor 38 53 0.14
Lauren type
Diffuse 41 50
Intestinal 42 43 0.56
T stage
T in situ 21
T1 6 10
T2 29 25
T3 43 56
T4 3 1 0.44
N stage
N0 23 29
N1 51 49
N2 7 13
N3 2 2 0.58
M stage
M0 81 91
M1 2 2 0.91
Overall TNM stage
02 1
I1 1 2 0
II 33 21
III 31 48
IV 6 3 0.045
Abbreviations: HIF¼hypoxia inducible factor; TNM¼tumour node metastasis.
aOne
patient with a missing slide was excluded. *w
2 P-value.
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sDISCUSSION
Hypoxia-inducible factor-1a expression increased in density and
intensity with progression from normal mucosa to gastric cancer.
This finding is consistent with other studies showing HIF-1a was
not expressed in normal tissue but seen at an increasing level
during the pathological process of cancer development, progres-
sion and loss of differentiation (Zhong et al, 1999), and that
staining increased in breast (Bos et al, 2001), skin (Costa et al,
2001) and cervical (Acs et al, 2003) carcinogenesis. We studied
HIF-1a expression in gastric biopsies corresponding with
the proposed sequence of gastric carcinogenesis. It must be
emphasised, however, that this model does not apply to gastro-
oesophageal junction tumours. Gastro-oesophageal adenocarcino-
mas (Siewert Type I and II tumours) arise via a similar sequence of
histopathological events, however, the initiating, promoting and
molecular factors are different to gastric cancer carcinogenesis
(Jankowski et al, 2000). Indeed, H. pylori appears to exert a
protective role in these types of tumours (Chow et al, 1998).
The molecular mechanisms of gastric cancer development are
unknown. Infection with H. pylori is the major initiating and
driving factor, with the proposal that the formation of ROS owing
to neutrophil infiltration in response to H. pylori infection causes
epithelial cell injury and progressive DNA damage (Obst et al,
2000). In addition to ROS, another important mediator in the
chronic inflammatory process is nitric oxide (NO), which, in
response to H. pylori infection, is produced by gastric epithelial
and non-epithelial cells from L-arginine via inducible-nitric oxide
synthase (iNOS). Increased iNOS expression is seen in H. pylori
infected gastric mucosa (Mannick et al, 1996; Pignatelli et al,
1998). A study also observed increased VEGF expression and new
microvessel formation in H. pylori infected gastric mucosa
(Tuccillo et al, 2005). Our observation that HIF-1a expression is
an early feature of gastric carcinogenesis suggests it may play a
role in promoting molecular changes that drive tumour formation.
As the normal architecture and vascular supply of gastritis-
associated mucosa and intestinal metaplasia is presumably
maintained, HIF-1a expression in these specimens is probably
not related to cellular hypoxia, but to inflammatory processes. In
Table 3 Distribution of 173
a patients according to tumour HIF-1a
staining pattern
Pattern of HIF-1a staining
Factor
HIF-1a focal
positivity
HIF-1a
negative
HIF-1a at the
invasive edge P*
Differentiation
Well 4 12 2
Mod 20 33 14
Poor 25 38 25 0.37
Lauren type
Diffuse 24 41 23
Intestinal 25 42 18 0.74
T Stage
T in situ 12 0
T1 7 6 3
T2 18 29 6
T3 22 43 32
T4 1 3 0 0.087
N Stage
N0 22 23 5
N1 20 51 28
N2 6 7 7
N3 1 2 1 0.034
M stage
M0 48 81 40
M1 1 2 1 0.99
Overall TNM stage
01 2 0
I1 6 1 1 3
II 13 33 7
III 17 31 30
IV 2 6 6 0.001
Abbreviations: HIF¼hypoxia inducible factor; TNM¼tumour node metastasis.
aThree patients with diffusely positive HIF-1a staining and one patient with a missing
slide were excluded. *w
2 P-value.
Table 4 Univariate survival analysis of putative prognostic factors
following surgical resection for gastric and gastro-oesophageal cancer
Overall survival Cancer-specific survival
Parameter HR 95% CI P* HR 95% CI P*
HIF
01 — — 1 —
1/2/3/4 1.1 0.8–1.4 0.62 1.0 0.7–1.5 0.82
HIF
Negative 1 — — 1 — —
Focal 0.9 0.5–1.3 0.49 0.7 0.5–1.2 0.26
Invasive edge 1.6 1.0–2.4 0.042 1.6 1.0–2.5 0.047
Diff
Well 1 — — 1 — —
Mod 2.9 1.4–6.2 0.005 3.4 1.3–8.5 0.011
Poor 3.7 1.8–7.8 0.001 5.3 2.1–13.3 0.001
Lauren type
Intestinal 1 — — 1 — —
Diffuse 1.4 1.0–2.0 0.052 1.8 1.2–2.6 0.003
Location
Non-GOJ 1 — — 1 — —
GOJ 1.4 1.0–2.0 0.083 1.5 1.0–2.2 0.059
T stage
T0/1 1 — — 1 — —
T2 2.6 1.0–6.7 0.052 5.2 1.2–22.0 0.023
T3 4.8 1.9–12.0 0.001 9.6 2.3–39.0 0.002
T4 16.8 4.4–64.2 0.0001 37.5 6.8–207.6 0.0001
N stage
N0 1 — — 1 — —
N1 2.0 1.3–3.0 0.003 2.5 1.5–4.1 0.001
N2 3.5 1.9–6.4 0.0001 4.8 2.5–9.2 0.0001
N3 4.2 1.5–12.0 0.008 5.7 1.9–16.9 0.002
M stage
M0 1 — — 1 — —
M1 2.6 1.0–7.1 0.062 2.9 1.1–7.9 0.037
Overall TNM stage
0/1 1 — — 1 — —
2 1.4 0.8–2.6 0.25 1.8 0.9–3.6 0.12
3 3.3 1.9–5.9 0.0001 4.5 2.3–8.8 0.0001
4 7.6 3.3–17.5 0.0001 10.9 4.4–27.1 0.0001
R class
R0 1 — — 1 — —
R1 2.3 1.6–3.3 0.0001 2.7 1.8–4.0 0.0001
R2 5.8 2.9–11.6 0.0001 7.2 3.6–14.5 0.0001
Abbreviations: CI¼confidence interval; HR¼hazard ratio; TNM¼tumour node
metastasis. *Obtained using a univariate Cox-proportional hazards model.
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ssupport of this idea, a recent cell line study showed the non-
hypoxic stabilisation of HIF-1a by ROS produced from H. pylori
(Park et al, 2003). Also, NO was shown to interfere with HIF-1a
prolyl hydroxylases under normoxia, preventing degradation and
resulting in HIF-1a accumulation and activation (Metzen et al,
2003). It may be, therefore, that in distal intestinal gastric cancer
development H. pylori induced ROS and NO lead to HIF-1a
stabilisation, which then plays a role in the stimulation of cell
proliferation, protection from apoptosis and other molecular
changes important in driving tumorigenesis. The observation that
H. pylori infection induces gastric dysplasia in TP53 knockout but
not wild-type mice highlights the obvious importance of genetic
changes in tumorigenesis (Fenoglio-Preiser et al, 2003). Never-
theless, a recent paper showed that HIF-1a induces genetic
instability and ‘provided molecular insights into the mechanisms
underlying hypoxia-induced genetic instability’ (Koshiji et al,
2005). It may be, therefore, that HIF-1a is involved in a process of
inflammation-mediated genetic instability.
Hypoxia-inducible factor-1a expression (positive vs negative)
had no prognostic significance in patients with surgically treated
1.0
HIF-1 Neg
HIF-1 Neg
HIF-1 Focalty positive (FP)
HIF-1 Invasive edge (IE) HIF-1 Pos
0.9
0.8
All tumours (n=176) AB
CD
EF
All tumours (n=173)
Gastric tumours
Gastro-oesophageal junction tumours Gastro-oesophageal junction tumours
Gastric tumours
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0 1 22 43 64 86 07 2
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0 1 22 43 64 86 07 2
1.0
0.9
0.8
0.7
0.6
0.5
C
a
n
c
e
r
-
s
p
e
c
i
f
i
c
 
s
u
r
v
i
v
a
l
Survival (months)
0.4
0.3
0.2
0.1
0.0
0 1 22 43 64 86 07 2
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0 1 22 43 64 86 07 2
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0 1 22 43 64 86 07 2
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0 1 22 43 64 86 07 2
P=0.82
At risk
Neg
Pos
83
93
At risk
Neg
Pos
28
52
At risk
Neg
Pos
55
41
42
27
28
12
21
9
13
5
11
3
6
2
22
39
14
24
9
13
7
6
6
4
3
4
At risk
Neg
FP
IE
83
49
41
At risk
Neg
FP
IE
28
30
20
At risk
Neg
FP
IE
55
19
21
42
15
10
28
6
4
21
5
3
13
3
2
11
2
1
6
1
1
22
25
12
14
15
7
9
8
3
7
4
2
6
2
2
3
2
2
64
41
23
42
22
12
31
14
6
21
7
3
18
4
2
10
3
2
64
66
42
37
31
22
21
12
18
7
10
6
P=0.019
P=0.93 P=0.16
P=0.3 P=0.092
Figure 2 HIF-1a expression and patient outcome in patients with non-cardia gastric cancers or gastro-oesophageal junction tumours. Left hand column
shows HIF-1a negative (score 0) vs positive (scores 1/2/3/4) expression (n¼176). The right hand column shows HIF-1a expression pattern categorised as
invasive edge, negative or focally positive (n¼173; 3 tumours with diffuse expression were excluded). Log-rank P-values are given.
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sgastric and gastro-oesophageal junction adenocarcinoma. Our
finding agrees with a study of 146 Japanese patients, mainly with
distal gastric cancer (Urano et al, 2006), and with some published
reports showing HIF-1a has no prognostic significance in cervical
(Haugland et al, 2002; Hutchison et al, 2004), colorectal
(Yoshimura et al, 2004) and ovarian (Birner et al, 2001) cancers.
In contrast, two further studies in gastric cancer showed HIF-1a
expression was an adverse prognostic factor in multivariate
analyses (Mizokami et al, 2006; Sumiyoshi et al, 2006). Hypoxia-
inducible factor-1a was associated with poor clinicopathological
features, VEGF expression and microvessel invasion (Mizokami
et al, 2006). The combination of HIF-1a and non-functional TP53
expression indicated an extremely poor prognosis (Sumiyoshi
et al, 2006).
In our study, two predominant types of HIF-1a expression were
observed: staining of the tumour’s invasive edge and focally
positive staining. Hypoxia-inducible factor-1a staining of the
invasive edge was associated with aggressive tumour character-
istics such as lymph node metastases and worse overall stage.
Other studies have noted HIF-1a expression at the invasive edge
of tumours (Zhong et al, 1999; Zagzag et al, 2000), but have not
performed survival analyses. In our analyses tumours with
invasive edge staining had a worse prognosis compared with
either HIF-1a negative or focal expression. Similarly the HIF-1a
regulated CA9 was expressed at the invasive tumour edge in a
subset of gastric cancer (Chen et al, 2005a) where it was associated
with tumour invasion, advanced disease and a poor prognosis.
Other authors showed that different patterns of HIF-1a expression
were associated with different survival characteristics (Vleugel
et al, 2005). In a study in breast cancer (Vleugel et al, 2005), peri-
necrotic HIF-1a was associated with the expression of CA9 and
Glut-1 and a poor prognosis. However, the diffuse staining type
had a more favourable prognosis and was not associated with CA9
or Glut-1 expression.
We found that focally positive HIF-1a expression was associated
with a less aggressive tumour phenotype and an improved
prognosis. Some studies have found that HIF-1a expression in
head and neck (Beasley et al, 2002), non-small cell lung (Volm
and Koomagi, 2000) and renal cell (Lidgren et al, 2005) cancer is
associated with an improved survival. However, as described in the
Introduction, most studies have shown HIF-1a expression is
associated with a poor prognosis (Griffiths et al, 2005). It has been
suggested that HIF-1a expression may be a less important
prognostic factor in surgically treated patients as the major
influence of hypoxia-induced radiation resistance is lacking
(Beasley et al, 2002). However, studies in patients with cervical
cancer who underwent radiotherapy showed either a trend towards
improved prognosis (Mayer et al, 2004) or an improved prognosis
in a subgroup of patients (Hutchison et al, 2004). Although
differences in staining and scoring methods cannot be ruled out
completely, differences in prognostic outcome observed in
numerous studies may reflect the differential regulation by
HIF-1a of a range of downstream target molecules. This
differential regulation might also be determined in individual
tumours by the different processes leading to HIF-1a stabilisation
(e.g. hypoxia/oncogene/ROS).
Hypoxia-inducible factor-1a can have both pro- and antiapop-
totic effects (Piret et al, 2002), and can also both stimulate
(Carmeliet et al, 1998) and inhibit (Bacon and Harris, 2004)
proliferation. There is evidence for communication between HIF-
1a and p53; p53 can stabilise HIF-1a and vice versa (Greijer and
van der Wall, 2004; Schmid et al, 2004). Also, HIF-1a phosphor-
ylation status may determine whether it acts to promote or check
tumour cell survival. Dephosphorylated HIF-1a stabilised p53 and
induced apoptosis, whereas phosphorylated HIF-1a bound to
HIF-1b to form the HIF-1 transcription factor thereby promoting
tumour growth (Suzuki et al, 2001). There is likely to be an
intricate balance between the different roles of HIF-1a, which
might be determined by the cumulative effect of multiple
interactions within a cell. In the series of gastric cancer patients
studied here, therefore, the beneficial effect of a focal pattern of
HIF-1a expression on prognosis may relate to its proapoptotic and
antiproliferative.
A final consideration that might play a role in determining
whether HIF-1a expression is a good or bad prognostic factor is
any contribution from other members of the HIF family. There are
two other homologues of the a-subunit (HIF-2a and HIF-3a),
which have different downstream actions and prognostic effects. A
recent study showed that HIF-1a and HIF-2a upregulate different
genes (Wang et al, 2005). Studies in non-small cell lung cancer and
malignant melanomas showed that HIF-2a expression was related
to a poor outcome when HIF-1a was not (Giatromanolaki et al,
2001, 2003). These findings raise the possibility of tissue specific
differences in the relative importance of HIF proteins in
determining tumour progression and prognosis. The clinical
relevance of different HIF proteins and variants, therefore, will
be of interest for future research in gastric cancer.
In conclusion, HIF-1a expression is an early event in gastric
carcinogenesis and is apparent in specimens infected by H. pylori.
Gastric biopsy specimens of intestinal metaplasia, dysplasia and
intestinal type adenocarcinoma show a progressively increased
density and intensity of HIF-1a staining. The prognostic impact of
HIF-1a expression in gastric cancer appears to be dependent on
the staining pattern with HIF-1a expression at the invasive tumour
edge associated with a poor prognosis and focally positive
expression a better prognosis. This relationship with a good
outcome might be related to the proapoptotic and antiproliferative
effects of HIF-1a. We hypothesise that variation in survival
associated with different staining patterns may be related to the
differential regulation by HIF-1a of a range of downstream target
molecules.
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